Novartis pays $2B to land a startup’s breast cancer drug
Source: BioPharma Dive - Latest News
Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.